Expression level of lncRNA SNHG15 in gastric cancer and clinical significance

doi:10.3969/j.issn.1673-8640.2022.05.002

Abstract

Abstract: Objective To investigate the clinical significance of long non-coding RNA（lncRNA） small nuclear RNA host gene 15（SNHG15） in gastric cancer. Methods A total of 97 patients with gastric cancer who underwent elective radical surgery were enrolled. The clinical data of all the patients were collected,and real-time quantitative polymerase chain reaction（PCR） was used to determine the relative expression levels of SNHG15 in gastric cancer tissue and normal gastric mucosal tissue. All the patients were followed up for 5 years from the 1st day after the operation. Survival analysis was performed by Kaplan-Meier survival curve,and prognostic factors were analyzed by Cox proportional hazard model. Results The relative expression level of SNHG15 in gastric cancer tissue was higher than that in normal gastric mucosal tissue（P<0.001）. The differences of the relative expression levels of SNHG15 in gastric cancer tissues with different degree of differentiation,TNM stage,depth of invasion and lymph node metastasis had statistical significance（P<0.05）. Kaplan-Meier survival curve analysis showed that the average survival time and 5-year survival rate of patients in low expression（SNHG15≤2.18） group were higher than those in high expression（SNHG15>2.18） group（P<0.001）. Cox proportional hazard model analysis showed that poorly differentiation,TNM stage Ⅲ-Ⅳ,lymph node metastasis and the expression of SNHG15 were risk factors that affected the prognosis of gastric cancer patients [hazard ratios（HR） were 0.381,2.568,2.892 and 4.851]. Conclusions The expression of SNHG15 in gastric cancer tissues is increased significantly,and it is related to the prognosis of patients,or can be used as a potential marker for gastric cancer mechanism research and prognosis evaluation.

Key words: Small nuclear RNA host gene 15, Long non-coding RNA, Gastric cancer

JI Ye, YUAN Xiaosun, ZHANG Lei, MA Huili, DONG Wei, LI Changsheng, ZHANG Jingwei, REN Zhonghai, ZHANG Yifei. Expression level of lncRNA SNHG15 in gastric cancer and clinical significance[J]. Laboratory Medicine, 2022, 37(5): 409-412.

Figures/Tables 3

References 13

[1]	MAKUUCHI R, IRINO T, TANIZAWA Y, et al. Esophagojejunal anastomotic leakage following gastrectomy for gastric cancer[J]. Surg Today, 2019, 49(3):187-196. DOI URL
[2]	刘谦, 夏兴洲, 李金丽, 等. miR-1269在胃癌及胃黏膜癌前病变组织中表达及其临床意义[J]. 胃肠病学和肝病学杂志, 2019, 28(11):1242-1246.
[3]	QIAN X, ZHAO J, YEUNG P Y, et al. Revealing lncRNA structures and interactions by sequencing-based approaches[J]. Trends Biochem Sci, 2019, 44(1):33-52. DOI URL
[4]	周原世, 高泽玮, 黄荣菊, 等. 恶性肿瘤发生发展中小核仁RNA宿主基因15的作用及机制[J]. 中华实用诊断与治疗杂志, 2019, 33(10):1029-1032.
[5]	LI M, BIAN Z, JIN G, et al. LncRNA-SNHG 15 enhances cell proliferation in colorectal cancer by inhibiting miR-338-3p[J]. Cancer Med, 2019, 8(5):2404-2413. DOI URL
[6]	潘思远, 房静远. 胃癌靶向治疗的研究进展[J]. 中华内科杂志, 2020, 68(2):148-152.
[7]	CHI Y, WANG D, WANG J, et al. Long non-coding RNA in the pathogenesis of cancers[J]. Cells, 2019, 8(9):1015. DOI URL
[8]	朱立新, 胡家龙. lncRNA/lncRNA-ATB与胃癌的相关性研究进展[J]. 中国临床研究, 2020, 33(2):268-271.
[9]	林胜. MT1-MMP、LncRNA SNHG15、YAP联合检测在甲状腺癌中的诊断价值[J]. 国际检验医学杂志, 2019, 40(4):431-434.
[10]	SUN X, BAI Y, YANG C, et al. Long noncoding RNA SNHG15 enhances the development of colorectal carcinoma via functioning as a ceRNA through miR-141/SIRT1/Wnt/β-catenin axis[J]. Artif Cells Nanomed Biotechnol, 2019, 47(1):2536-2544. DOI URL
[11]	马秦榕, 魏亚敏, 傅仁秀, 等. LncRNA SNHG12、SNHG15及SNHG16在肺腺癌的表达及意义[J]. 诊断病理学杂志, 2019, 26(5):278-282.
[12]	QU C, DAI C, GUO Y, et al. Long noncoding RNA SNHG15 serves as an oncogene and predicts poor prognosis in epithelial ovarian cancer[J]. Onco Targets Ther, 2018, 12:101-111. DOI URL
[13]	DONG Y Z, MENG X M, LI G S. Long non-coding RNA SNHG15 indicates poor prognosis of non-small cell lung cancer and promotes cell proliferation and invasion[J]. Eur Rev Med Pharmacol Sci, 2018, 22(9):2671-2679.

临床病理特征	例数	SNHG15	临床病理特征	例数	SNHG15
性别			Lauren分型
男性	59	2.37±0.22	肠型	39	2.39±0.21
女性	38	2.30±0.21	弥漫及混合型	58	2.32±0.22
t值		1.492	t值		1.488
P值		0.139	P值		0.140
年龄			TNM分期
>57岁	54	2.34±0.23	Ⅰ~Ⅱ期	40	2.25±0.19
≤57岁	43	2.35±0.21	Ⅲ~Ⅳ期	57	2.41±0.22
t值		0.128	t值		3.864
P值		0.898	P值		<0.001
肿瘤部位			浸润深度
胃窦	54	2.33±0.21	T₁~T₂	31	2.23±0.14
胃底和胃体	43	2.37±0.23	T₃~T₄	66	2.40±0.23
t值		0.825	t值		3.761
P值		0.411	P值		<0.001
肿瘤大小			淋巴结转移
≥5 cm	55	2.36±0.22	是	62	2.38±0.23
<5 cm	42	2.32±0.21	否	35	2.28±0.19
t值		0.919	t值		2.406
P值		0.360	P值		0.018
分化程度
低分化	61	2.39±0.23
中高分化	36	2.28±0.19
t值		2.469
P值		0.015

临床病理特征	例数	SNHG15	临床病理特征	例数	SNHG15
性别			Lauren分型
男性	59	2.37±0.22	肠型	39	2.39±0.21
女性	38	2.30±0.21	弥漫及混合型	58	2.32±0.22
t值		1.492	t值		1.488
P值		0.139	P值		0.140
年龄			TNM分期
>57岁	54	2.34±0.23	Ⅰ~Ⅱ期	40	2.25±0.19
≤57岁	43	2.35±0.21	Ⅲ~Ⅳ期	57	2.41±0.22
t值		0.128	t值		3.864
P值		0.898	P值		<0.001
肿瘤部位			浸润深度
胃窦	54	2.33±0.21	T₁~T₂	31	2.23±0.14
胃底和胃体	43	2.37±0.23	T₃~T₄	66	2.40±0.23
t值		0.825	t值		3.761
P值		0.411	P值		<0.001
肿瘤大小			淋巴结转移
≥5 cm	55	2.36±0.22	是	62	2.38±0.23
<5 cm	42	2.32±0.21	否	35	2.28±0.19
t值		0.919	t值		2.406
P值		0.360	P值		0.018
分化程度
低分化	61	2.39±0.23
中高分化	36	2.28±0.19
t值		2.469
P值		0.015

指标	β值	Wald值	P值	HR（95%可信区间）
性别	-0.185	0.372	0.542	0.831（0.459~1.505）
年龄	-0.091	0.098	0.754	0.913（0.516~1.615）
肿瘤部位	-0.064	0.047	0.828	0.938（0.526~1.671）
肿瘤大小	-0.036	0.016	0.899	0.964（0.550~1.690）
分化程度	-0.965	5.091	0.024	0.381（0.165~0.881）
Lauren分型	0.416	1.730	0.188	1.516（0.816~2.816）
TNM分期	0.943	4.245	0.039	2.568（1.047~6.299）
浸润深度	-0.414	0.758	0.384	0.661（0.261~1.677）
淋巴结转移	1.062	7.345	0.007	2.892（1.342~6.232）
SNHG15表达	1.579	10.159	0.001	4.851（1.837~12.809）

指标	β值	Wald值	P值	HR（95%可信区间）
性别	-0.185	0.372	0.542	0.831（0.459~1.505）
年龄	-0.091	0.098	0.754	0.913（0.516~1.615）
肿瘤部位	-0.064	0.047	0.828	0.938（0.526~1.671）
肿瘤大小	-0.036	0.016	0.899	0.964（0.550~1.690）
分化程度	-0.965	5.091	0.024	0.381（0.165~0.881）
Lauren分型	0.416	1.730	0.188	1.516（0.816~2.816）
TNM分期	0.943	4.245	0.039	2.568（1.047~6.299）
浸润深度	-0.414	0.758	0.384	0.661（0.261~1.677）
淋巴结转移	1.062	7.345	0.007	2.892（1.342~6.232）
SNHG15表达	1.579	10.159	0.001	4.851（1.837~12.809）

[1]	WANG Tengfei, CHEN Shan, AN Hebing, ZHOU Lei. Expressions and roles of lncRNA CRNDE and miR-384 in peripheral blood of patients with acute leukemia [J]. Laboratory Medicine, 2023, 38(7): 686-691.
[2]	LIU Ruili, LI Lanjun, JIA Minlei, WANG Yihui, HAO Weina. Correlation between tumor miR-7-5p and NOVA2 levels and clinical prognosis in cancer tissues of patients with gastric cancer [J]. Laboratory Medicine, 2023, 38(4): 325-329.
[3]	ZHOU Furong, LI Yanzhu, LIU Yonggan. Application of lncRNA SNP in colorectal cancer susceptibility prediction and prognosis assessment [J]. Laboratory Medicine, 2023, 38(12): 1206-1210.
[4]	GUO Shuang, LIU Hongli, LI Ya. Progression of migration and invasion-related miRNA and lncRNA in Epstein-Barr virus-associated gastric cancer [J]. Laboratory Medicine, 2023, 38(10): 987-996.
[5]	WANG Ruijuan, LI Chao, DUAN Lijuan, SHANG Miao, YANG Ruyu. Expression and clinical significance of lncRNA RBM5-AS1 in acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(1): 39-45.
[6]	WANG Rui, LI Zhaoyan, ZHAO Aiguang. Application of circulating tumor DNA detection in the diagnosis and treatment of gastric cancer [J]. Laboratory Medicine, 2022, 37(9): 877-881.
[7]	NIE Tian, RAN Zihan, JIN Lei. Research progress on the relationship between interleukin gene polymorphisms and gastric cancer [J]. Laboratory Medicine, 2022, 37(9): 882-886.
[8]	WANG Yuqing, ZHANG Yue, XU Wen, CUI Zhongqi. Construction and clinical application of colon cancer prognostic risk model of ferroptosis-related lncRNA [J]. Laboratory Medicine, 2022, 37(8): 720-728.
[9]	JI Ye, YUAN Xiaosun, ZHANG Lei, MA Huili, XUE Yongfei, LI Changsheng, ZHANG Jingwei, REN Zhonghai, ZHANG Tengfei. Expression of lncRNA HULC in papillary thyroid carcinoma tissues [J]. Laboratory Medicine, 2022, 37(7): 605-609.
[10]	LIANG Chunfang, ZHU Kangning, ZHANG Qi. Serum miR-21 and miR-135a expression levels in predicting the recurrence and metastasis of gastric cancer patients after chemotherapy [J]. Laboratory Medicine, 2022, 37(5): 417-422.
[11]	ZHOU Huan, TANG Ying, DU Cuiping, YANG Yang, FENG Huijie, QIU Miaoxin, YAN Peiyi, CAI Xiaoyao, JIN Shu. Effect of long non-coding RNA SNHG5 on the transcriptome of human hypopharyngeal carcinoma cells and clinical significance [J]. Laboratory Medicine, 2022, 37(3): 281-287.
[12]	MAO Zheng, QIAN Zengkun, YING Fei, WANG Zhaoli, XIAO Qun, CUI Fan. Correlation between E-Cad,G-17,HER-2 and postoperative recurrence risk of gastric cancer [J]. Laboratory Medicine, 2022, 37(1): 41-46.
[13]	XIONG Zhongbo, WANG Lei, YIN Beiqi, DAI Yue, WEI Xiaoqing, LU Pei. Clinical roles of SAA and CRP in pathological staging and metastasis of gastrointestinal cancer [J]. Laboratory Medicine, 2022, 37(1): 51-55.
[14]	XUE Yan, WANG Jiajia, WANG Fuxiang, REN Qiuwei. Relationship between the expressions of CLIC4 and SNHG3 and the prognosis of patients with Stage Ⅰ-Ⅱ ovarian cancer [J]. Laboratory Medicine, 2021, 36(10): 1026-1032.
[15]	HANG Chen, HUANG Biao, PENG Haixia, WEI Xin, XU Weihong, SHENG Huiming, LI Ningli. Role of TRFIA for detecting pepsinogen in screening ulcer gastric cancer [J]. Laboratory Medicine, 2020, 35(7): 721-725.